建邦科技(837242) - 2024 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 50.82% to CNY 75,656,075.46 for the period from January to September 2024, up from CNY 50,163,954.73 in the same period last year[4] - Operating revenue for the first nine months of 2024 reached CNY 537,469,590.17, reflecting a 36.15% increase from CNY 394,749,237.01 in the previous year[4] - Basic earnings per share increased by 42.68% to CNY 1.17 from CNY 0.82 year-on-year[4] - Operating profit increased by 44.87% to ¥98,256,300.01 due to a higher cumulative increase in operating revenue compared to total operating costs[6] - Net profit rose by 50.73% to ¥75,618,185.53, driven by an increase in total profit[6] - Total profit increased by 45.46% to ¥98,673,011.90, reflecting the growth in operating revenue[6] - Total operating revenue for the first nine months of 2024 reached ¥537,469,590.17, a significant increase of 36.2% compared to ¥394,749,237.01 in the same period of 2023[23] - Net profit for the first nine months of 2024 was ¥75,618,185.53, representing a 50.6% increase from ¥50,168,002.13 in 2023[25] Cash Flow - Cash flow from operating activities improved by 81.68% to CNY 57,727,366.12 compared to CNY 31,774,806.77 in the same period last year[4] - Cash flow from operating activities generated ¥57,727,366.12, compared to ¥31,774,806.77 in the same period of 2023, indicating a significant improvement[28] - Net cash flow from operating activities was ¥62,041,640.61, up 78.5% compared to ¥34,838,948.44 in the previous year[30] - Cash received from sales of goods and services was ¥520,852,280.40, compared to ¥362,873,274.31 in the same period last year, reflecting a 43.5% increase[30] Assets and Liabilities - Total assets increased by 10.77% to CNY 777,306,831.40 as of September 30, 2024, compared to CNY 701,757,889.06 at the end of 2023[4] - Total liabilities increased to CNY 218,016,934.21, up from CNY 196,836,092.78, reflecting an increase of approximately 10.6%[19] - Shareholders' equity rose to CNY 559,289,897.19, compared to CNY 504,921,796.28, marking an increase of about 10.7%[19] - Current assets totaled CNY 682,398,771.96, an increase of 8.6% from CNY 628,514,961.04 at the end of 2023[18] - Total non-current assets amounted to CNY 94,908,059.44, an increase from CNY 73,242,928.02, reflecting a growth of approximately 29.5%[18] Expenses - Financial expenses decreased by 113.62% to ¥175,975.97 due to exchange rate fluctuations[6] - Management expenses rose by 35.16% to ¥26,079,568.51, primarily due to performance bonuses of ¥3,000,000 accrued during the reporting period[6] - Research and development expenses for the first nine months of 2024 were ¥15,994,640.55, an increase from ¥12,533,328.45 in 2023[23] Shareholder Information - The total number of ordinary shares at the end of the period was 64,485,500, with a slight decrease of 33,750 shares[9] - The largest shareholder, Zhong Yongduo, holds 50.70% of the shares, totaling 32,694,700 shares[10] Corporate Actions - The company established a subsidiary in Thailand, leading to a significant increase in other non-current assets by 139.42% to CNY 41,833,788.59[5] - The company approved the use of up to RMB 75 million of temporarily idle raised funds for cash management, ensuring it does not affect the implementation of fundraising investment projects[14] - A total of 33,750 restricted shares were repurchased and canceled due to the voluntary departure of certain incentive targets[15] - The company has three active stock incentive plans currently in progress, which are expected to enhance employee motivation and retention[14] Compliance and Commitments - The company has not engaged in any external guarantees or loans during the reporting period[12] - There were no significant litigation or arbitration matters affecting the company during the reporting period[12] - The company has disclosed its commitments and their fulfillment status in its annual report[16] - The company conducted daily related transactions with a related party, ensuring compliance with internal approval procedures[12]